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Abstract
Background: The Nottingham Prognostic Index (NPI), which combines numerical values for nodal status, tumor
size and histological grade, is used in the standard of care to provide predictive value information on post-surgery
survival for patients with primary breast cancer. Attempts to improve the performance of the NPI algorithm have
been carried out by testing the inclusion of other biomarker expression and morphological features such as
vascular invasion. In the present study, we investigated whether expression of the autocrine growth and survival
factor GP88 (progranulin), known to be overexpressed in breast cancer, would improve NPI’s predictive value.
Methods: We examined by immunohistochemistry (IHC) the GP88 expression in 508 cases of estrogen receptor
positive invasive ductal carcinoma with known clinical outcomes and for which NPI had been determined. GP88
IHC expression was scored by two board certified pathologists and classified into two score groups of GP88 <3+ (0,
1+, 2+) and GP88 = 3+. The correlation between GP88 scoring, NPI and disease-free (DFS) or overall survival (OS)
outcomes was then examined by Kaplan-Meier analysis, Cox proportional Hazard (CPH) ratio and Pearson’s X2 test.
Results: Kaplan-Meier survival graphs of cases categorized by their NPI scores (<3.4, 3.4–5.4, >5.4) and GP88
expression showed that for patients within the same NPI subgroup, patients having tumors with a high GP88
expression (GP88 IHC score of 3+) had a worse DFS than patients with tumors that had a low GP88 expression
(GP88 IHC score <3+). When adjusted for NPI, high GP88 score was significantly associated with recurrence with a
hazard ratio of 3.30 (95 % CI 2.12 to 5.14).
Conclusions: The data suggest that the determination of GP88 tumor expression at time of diagnosis for early
stage breast cancer patients can provide additional survival information to that provided by NPI alone and thus
may be useful for risk management of patients diagnosed with breast cancer.
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Background
Prognostic factors are used to provide information on
the clinical management of patients. In the case of
breast cancer patients, the common prognostic factors
are tumor size, histological grade, histological nodal
status and patient’s age. Estrogen and progesterone
receptor and HER-2 expression provide additional infor-
mation and guideline for treatment decisions. Addition-
ally, proliferation markers such as DNA ploidy, S
fraction or Ki67 expression are increasingly examined
and incorporated for risk evaluation at time of diagnosis.
Such factors might be used to discriminate among pa-
tients at increased risk of recurrence from the ones at
low risk and thus identify patients that may benefit from
adjuvant therapy from the ones more likely to display
treatment resistance. Some tumor characteristics have
been used to define a prognostic index such as the
Nottingham prognostic index (NPI) proposed in 1982 [1].
The NPI was initially derived from a retrospective
study of 382 patients with operable primary breast
cancers. This finding was confirmed after long-term
follow-up [2] and was independently validated in other
multi-center studies [3, 4]. The calculated NPI predict-
ing survival includes tumor and disease characteristics
such as tumor size, histological grade and nodal status
and is defined by the following formula: NPI = tumor
size (cm) x 0.2 + grade (I-III) + lymph node score (1–3).
Patients are typically stratified into three NPI categories
associated with different survival outcomes: <3.4 (good
prognosis group), 3.4–5.4 (medium prognosis group)
and >5.4 (poor prognosis group). As with most prognos-
tic algorithms, within the stratified NPI groups, there
are patients that do less well than the rest of the group
and as such there is a need to determine if NPI stratifi-
cation can be further improved to better stratify patients
within the NPI groups.
In recent years, there have been several attempts to in-
crease the predictive value of NPI by combining NPI scores
with the expression of prognostic biomarkers [5, 6]. In the
present paper, we examined the predictive value of the
autocrine growth and survival factor GP88/Progranulin in
combination with NPI to determine whether adding
GP88/Progranulin tumor expression determination to
NPI scoring could provide additional prognostic infor-
mation and further stratify patients in low and high
risk recurrence groups within each NPI category.
The 88 kDa, cysteine-rich glycoprotein GP88 (also
known as Progranulin, PCDGF, granulin/epithelin pre-
cursor or acrogranin) is the largest member of a unique
family of growth factors that plays a role as growth and
survival factor and is characterized by 7 and a half re-
peats of a distinct double cysteine-rich granulin/epithelin
motif [7–9]. Initially identified as being overexpressed in
breast cancer, GP88 has since been reported by many
investigators to be overexpressed in several other human
cancers while normal corresponding tissues display little
or no GP88 expression [10–12].
In breast cancer, GP88 expression is associated with
increased tumorigenesis and it mediates in part, cancer
cell growth, survival, resistance to therapy (anti-estrogen,
Herceptin and doxorubicin) and several hallmarks of
metastasis such as invasion, angiogenesis and migration
[13–16]. The pathways activated by GP88 signaling in-
clude the mitogen-activated protein kinase (ERK 1/2),
and phosphatidylinositol 3-kinase (PI-3 K), leading to
the activation of the cell cycle regulatory proteins such
as Cyclin D1, Cyclin B and CDK4 [14, 17, 18].
In human breast carcinomas, GP88 is highly expressed
in both estrogen receptor positive (ER+) and estrogen re-
ceptor negative (ER-) cells. Inhibition of GP88 expres-
sion by GP88 antisense cDNA or SiRNA resulted in
inhibition of cell proliferation and reduction of tumor
incidence and tumor size in nude mice [14]. In ER+ cells,
GP88 overexpression was associated with estrogen inde-
pendence and acquisition of resistance to the anti-
estrogen tamoxifen, faslodex and the aromatase inhibitor
letrozole [17, 19, 20]. Immunohistochemistry (IHC)
studies of formalin-fixed paraffin-embedded (FFPE)
tumor specimens demonstrated that GP88 tumor tissue
expression was low or negative in normal mammary tis-
sues and lobular carcinoma whereas it was elevated in
ductal carcinoma in situ (DCIS) and invasive ductal car-
cinoma (IDC) tissues [21]. In IDC, high GP88 expression
positively correlated with p53 expression and Ki67 index
whereas it was independent of HER2 expression [21].
Based on the fact that GP88 expression in ER+ cells was
associated with estrogen independence and tamoxifen
resistance [17], analysis of GP88 tissue expression in
~600 cases of ER+ IDC in relation with clinical out-
comes demonstrated that high GP88 expression (IHC
score of 3+) was associated with a 5.9-fold higher hazard
of disease recurrence (p < 0.0001) and a 2.5-fold higher
mortality hazard (p = 0.0002) compared to patients with
no or low tumor GP88 expression [22]. Since GP88 is a
secreted protein, it can also be found in the circulation
and is measurable in serum using an Enzyme Immuno-
assay (EIA) developed in our laboratory. A longitudinal
clinical study demonstrated the performance of the
serum GP88 EIA by establishing a basal range for GP88
in serum from healthy volunteers of 28.7 ± 5.8 ng/ml
and showing that serum GP88 levels in breast cancer pa-
tients was elevated to 40.7 ± 16.0 ng/ml in early stage
and over 100 ng/ml in later stages of breast cancer [23].
These studies demonstrated the importance of GP88 as
a risk predictor of breast cancer survival.
Based on these observations, the present study focused
on determining whether associating GP88 IHC tumor
tissue scores to NPI determination would increase NPI
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The breast cancer patient cohort used for this study con-
sisted of 574 cases of ER+ IDC diagnosed between 1985
and 2003 collected from six geographically distinct US
institutions: Kaiser Permanente, (Portland, OR), Kaiser
Permanente (Miami, FL), Washington University, (St
Louis, MO), University of Miami, (Miami, FL), Fox
Chase Cancer Center (Philadelphia, PA), the EEH Breast
Cancer Research and Treatment Center (Baton Rouge,
LA). The first four sites were part of the Cooperative
Breast Cancer Tissue Resources (CBCTR) from the
National Cancer Institute [24].
The retrospective patients’ information and material
were de-identified and given new unique case numbers
prior to shipment. The study was reviewed and approved
by the Chesapeake Research Review’s IRB (CRRI
1006001). The board confirmed that informed consent
was not required for this study.
Upon histological examination, 31 cases contained
slides with no evaluable tumor tissue and 35 additional
cases were missing some tumor characteristics informa-
tion required to determine NPI. As a result, these cases
were excluded from the final analysis. Therefore, the
final database for analysis included 508 cases. The infor-
mation about tumor size, lymph node status and tumor
grade for each patient provided in the database was used
to determine their NPI using the formula: NPI = Size
(cm) x 0.2 + grade (1–3) + lymph node score (1–3).
Three NPI categories were used: < 3.4 (good prognosis
group), 3.4–5.4 (medium prognosis group) and >5.4
(poor prognosis group) to stratify patients for analysis as
described in published reports.
GP88 expression by Immunohistochemistry
GP88 tissue expression was measured by IHC on sec-
tions of tissue from FFPE whole tissue blocks using
previously validated and described IHC methodology
[21, 22]. Briefly, for each case, individual 5 micron sec-
tions on positively charged microscope slides were
deparaffinized with xylene and rehydrated through a
graded ethanol series. Antigen retrieval was conducted
for 25 min in 0.2 M citrate buffer pH 6.0 in a 94 °C
water bath. Staining was carried out on a Dako Autostainer.
GP88 was detected in tissue sections by incubation with an
anti-human GP88 mouse monoclonal antibody, clone 6B3
from A&G Pharmaceutical Inc. (Precision Antibody Div-
ision) Columbia, MD, followed by washing, and incubation
with HRP-conjugated secondary goat anti-mouse antibody
(Dako, Carpinteria, CA). Bound antibody was detected
using DAB as chromogen (Dako). Slides were then washed
and counter-stained with Mayer’s Hematoxylin, prior to
examination and scoring.
Evaluation of GP88 immunohistochemistry results
GP88 cytoplasmic immunoreactivity was semi-quantitatively
scored as: <10 % of cells staining: negative (0); >10 % of
cells staining: positive with positive staining graded from
weak/focal (1+) to moderate/focal or diffuse (2+) to
strong/diffuse (3+) as described previously [21, 22]. The
immuno-stained slides were evaluated and scored by two
board certified pathologists who independently examined
the tissue sections while blinded to the clinical data.
Statistical analysis methods
Descriptive statistics were used to summarize the pa-
tients’ and tumors’ characteristics from these 508 cases.
Using the data from the 508 ER+ IDC cases, we estab-
lished the disease-free survival (DFS) and overall survival
(OS) for each patient. DFS was defined as the time inter-
val from date of diagnosis to first recurrence (local or
distant). In the same patient population, OS was defined
as the time interval from date of diagnosis to time of last
follow-up or death, regardless if breast cancer was the
primary or underlying cause of death. Time to recur-
rence was censored at the time of last disease-free
follow-up, and at death for those patients who died with-
out a previous recurrence.
The relevance of the NPI score to survival was verified
by fitting Kaplan-Meier (KM) curves for DFS and OS
stratified by NPI and the curves were compared using
the log rank tests. As an initial exploration of the inter-
play between NPI and GP88, KM curves stratifying sur-
vival by GP88 within each NPI category were fitted. P
values of the log rank test for the relevance of GP88
within each NPI category were calculated.
Finally, multivariate analyses using Cox Proportional
Hazard (CPH) models were carried out to test whether
the two markers (GP88 and NPI) provided separate in-
formation, additional to that delivered by other markers
for DFS and OS. All the calculations were performed in
R [25].
Results
Determination of the NPI scores of the study population
508 ER+ IDC cases were obtained from 6 geographically
distinct US institutions as described in the method sec-
tion. Cases were de-identified and obtained along with
clinical and pathological parameters provided by the tis-
sue repositories. These included age at diagnosis, disease
stage, tumor size, tumor grade, steroid receptor status
(estrogen and progesterone receptors), lymph node sta-
tus, adjuvant treatment (chemotherapy, hormone ther-
apy) and clinical outcomes such as recurrence and
survival information. All patients underwent surgery and
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none of the patients received neo-adjuvant therapy.
Since the menopausal status of patients was not pro-
vided in the database, age was used as a surrogate, with
patients aged >50 years old considered to be post-
menopausal for this analysis. Estrogen receptor status
and progesterone receptor status for the cases examined
had been determined by IHC using Ventana IHC kits
(Ventana, Tucson, AZ). All cases examined were ER+.
Median follow-up was 91.3 months. Descriptive statistics
were used to present the patient and tumor characteris-
tics (Table 1). NPI score was determined using the for-
mula provided in the method section. The distribution
of NPI scores within the 3 NPI categories (GPG ≤3.4;
MPG 3.4–5.4; PPG >5.4) provided in Table 1 shows that
the patients were fairly evenly distributed among the
three NPI categories.
A Kaplan-Meier analysis of DFS and OS for each of
the 3 NPI categories showed that as expected, DFS and
OS decreased when NPI score increased (Fig. 1). This
confirmed the relevance of the NPI in DFS and OS for
this patient population. Table 2 shows a cross-tabulation
of the patients by NPI category and identifies the DFS
probability at 60 months and 120 months for patients in
each NPI category. The table also lists the 95 % confi-
dence interval for the difference in survival probability
between each NPI category and the category above it, at
each of these times. The data show that DFS and OS
probabilities for the study population are within ac-
cepted ranges for the published NPI categories based on
published reports and confirm that as NPI score in-
creases, the patient survival decreases.
Stratification of NPI categories by GP88 expression
The 508 patients that were stratified in the three NPI
categories had their IHC GP88 tissue expression deter-
mined and scored as described in the method section.
GP88 IHC scores were then grouped as IHC scores of 3
+ and <3+ (0, 1+, 2+) as proposed previously [21, 22].
Representative photomicrographs of the staining for all
GP88 scores have been previously published [22]. Over-
all 12.2 % of the cases examined had elevated GP88 ex-
pression levels. A cross-tabulation of NPI score against
GP88 (Table 3) showed a strong association between
NPI and GP88 (chi-squared = 15.28, P = 0.0005). Going
from the lowest NPI risk category to the highest, the
proportion of patients with elevated GP88 expression in-
creased from 5.2 to 21.1 %, in agreement with the fact
that higher NPI category corresponded to decreased sur-
vival probability and that increased GP88 expression was
also associated with worse outcome.
We have previously established that GP88 expression
was strongly related to OS and to DFS [22]. The data of
Table 3 raised the question of whether the prognostic
value of GP88 was a consequence of this association
with conventional risk measures as summarized by NPI
or whether GP88 carried separate or additional prognos-
tic information on its own.
GP88 tissue expression further stratifies DFS and OS with
each NPI category
GP88 prognostic information was investigated in two
analyses. In the first, we examined Kaplan-Meier DFS
and OS functions for the patients within each NPI
grouping separated by their GP88 tissue expression with
IHC scores of <3+ and 3+ (Figs. 2 and 3). The data
showed that within each NPI category, the DFS
(Fig. 2 a–c) and OS (Fig. 3 a–c) probabilities of patients
with elevated GP88 (IHC score 3+) were lower than that
of patients with lower GP88 expression levels (IHC
score <3+). High GP88 expression was associated with
worse survival in each of the three NPI categories in Figs. 2
and 3 and this was quantified by the significant p values of
the associated logrank statistics as shown in Table 4. This
table shows high significance for GP88 in DFS in the NPI
Table 1 Patients and tumor characteristics of the study cohort
Characteristics Groups Number Percent
Age at Dx Median 61 N/A
Range 24–93 N/A
Race Caucasian 276 54
African American 42 8
Asian 8 2
Unknown 182 36
ER Positive 508 100
PR Positive 307 60
Negative 140 28
Unknown 61 12
Tumor size <2.5 cm 346 68
2.5–5 cm 137 27
>5 cm 25 49
Tumor grade Grade 1 46 9
Grade 2 220 43
Grade 3 242 48
Stage Stage 1 221 44
Stage 2 231 45
Stage 3 56 11
Lymph node Negative 267 53
Positive 241 47
NPI ≤3.4 155 30
3.4–5.4 244 48
>5.4 109 22
GP88 <3+ 446 88
3+ 62 12
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3.4–5.4 and >5.4 groups (p = 0.0002 and p = 0.0005 re-
spectively), but modest statistical significance in the DFS
NPI <3.4 group (p = 0.0698). In comparison, GP88 showed
statistical significance in the >5.4 NPI OS group (p =
0.0343) while in the other two groups GP88 showed
modest or no significance. However, this conclusion is
limited due to the small number of OS events in these
comparisons.
The final analysis performed was to quantify the infor-
mation from the KM analysis in a simultaneous test.
This second analysis was done using the CPH model
with DFS and OS as dependent variables. Three covari-
ates were used: the elevated GP88 indicator, an indicator
of NPI >3.4 and an indicator for NPI >5.4.
Table 5 demonstrates that, when adjusted for NPI, ele-
vated GP88 was highly significantly associated with re-
currence. Its hazard ratio was 3.30 (95 % CI 2.12 to
5.14). Having an NPI between 3.4 and 5.4 rather than
≤3.4 was also highly significant. It corresponded to a
hazard ratio of 2.13 (95 % CI 1.21 to 3.76). If the NPI ex-
ceeds 5.4, this added a further highly significant hazard
for recurrence – HR = 1.90 (95 % CI 1.23 to 2.95).
Concerning OS, Table 6 shows that, when adjusted for
NPI, GP88 was a highly significant indicator of overall
mortality with a hazard ratio of 1.89 (95 % CI 1.28 to
2.80). An NPI between 3.4 and 5.4 was not significantly
worse than NPI ≤3.4 but an NPI >5.4 was also a highly
significant indicator of mortality, with a hazard ratio of
1.95 (95 % CI 1.38 to 2.77).
Discussion
The ability to accurately evaluate risk of recurrence re-
mains a challenge in the current standard of care for
breast cancer patient management. In recent years
molecular biology based tests such as Oncotype Dx
(Genomic Health, Redwood City, CA) and MammaPrint
(Agendia, Irvine, CA) have been developed for stratifying
certain populations of breast cancer patients for risk of
recurrence based on the profile of several target genes
[26, 27]. However, such tests remain expensive and the
results are not applicable to all breast cancer popula-
tions. Alternatively, the use of a combination of markers
such as ER, PR, HER-2 and Ki67 together with disease
characteristics such as tumor size and lymph node
involvment has been somewhat useful in providing a risk
of recurrence assessment for breast cancer patients at
primary diagnosis. Since ER, PR, HER-2 and Ki67 are all
cost effective laboratory tests that can be performed in
most pathology laboratories, the investigation of add-
itional protein-based tissue biomarkers that are useful in
risk of recurrence prediction is important to improve
the clinical management of breast cancer patients.
The NPI is a widely used prognostic index based on a
combination of histopathological features which are
strong independent predictors of clinical outcomes such
as lymph node status, tumor size and tumor grade for
patients with invasive ductal carcinoma. NPI scores
stratify patients into three prognostic categories: good
Fig. 1 Disease Free Survival and Overall Survival for patients within each NPI category. The NPI was calculated for each of the 508 ER+ IDC cases.
Kaplan-Meier plots were fitted for DFS and OS for each of the 3 NPI categories (GPG <3.4 in red, MPG 3.4–5.4 in blue, GPG >5.4 in black)





60 months 120 months
≤3.4 94.6 (1.9) % 88.3 (2.9) %
3.4 to 5.4 84.3 (2.4) % 76.0 (3.3) %
CI 4.2–16.4 % 3.6–21.0 %
>5.4 70.4 (4.7) % 60.8 (5.5) %
CI 3.3–24.2 % 2.4–28.0 %
The percent disease-free survival (DFS) probability for each NPI group was
calculated for 60 and 120 months, standard errors are included in parenthesis.
The 95 % Confidence Intervals (CI) for the difference in survival probability
for ≤3.4 vs 3.4 to 5.4 and 3.4 to 5.4 vs >5.4 for each time-point are listed
Table 3 Distribution of GP88 expression within each NPI
category
NPI GP88
< 3+ 3+ Total
≤3.4 147 (94.8 %) 8 (5.2 %) 155 (30.5 %)
3.41–5.4 213 (87.3 %) 31 (12.7 %) 244 (48.0 %)
>5.4 86 (78.9 %) 23 (21.1 %) 109 (21.5 %)
Total 446 (87.8 %) 62 (12.2 %) 508 (100 %)
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prognosis group (GPG) with an NPI score of ≤3.4;
medium prognostic group (MPG) with an NPI score
3.4–5.4; and poor prognosis group (PPG) with an NPI
score of >5.4. Patients in the GPG group are potentially
spared chemotherapy and the associated side effects. In
support for its applicability to breast cancer patient
management, NPI has been verified prospectively and
validated in two large multicenter studies involving close
to 11,000 patients [3, 4].
Fig. 2 Disease Free Survival by GP88 score within the three NPI
groups. Using the NPI score calculated for each of the 508 ER+ IDC
cases, Kaplan-Meier plots were fitted for DFS functions for the
patients within each NPI grouping (a-GPG <3.4, b-MPG 3.4–5.4,
c-GPG >5.4) stratified by their GP88 tissue expression using the IHC
scores of <3+ in black solid line and 3+ in red dashed line
Fig. 3 Overall Survival by GP88 score within the three NPI groups.
Using the NPI score calculated for each of the 508 ER+ IDC cases,
Kaplan-Meier plots were fitted for OS functions for the patients within
each NPI grouping (a-GPG <3.4, b-MPG 3.4–5.4, c-GPG >5.4) stratified
by their GP88 tissue expression using the IHC scores of <3+ in black
solid line and 3+ in red dashed line
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One of the great advantages of NPI is its simplicity.
However, diverse strategies to improve the predictive
value of NPI have been explored. In particular, combin-
ing the analysis of certain biomarkers with NPI deter-
mination has resulted in providing additional risk
prediction information and refining the value of the NPI
determination. Multiple biomarkers of relevance to the
biology of mammary tumors have been investigated by
several laboratories. Callagy et al. [5] analyzed the ex-
pression of 13 biomarkers. They concluded that in uni-
variate analysis eight biomarkers showed a significant
association with survival at 10 years. Out of these 8 bio-
markers, only bcl-2 retained prognostic significance in-
dependent of NPI. They concluded that measuring bcl-2
expression in tumor biopsies was an independent pre-
dictor of breast cancer outcomes and could be useful as
a prognostic adjunct to NPI, particularly in the first
5 years after diagnosis. Parisi et al. [28] outlined the ben-
efits of the inclusion of biomarkers with clinico-
pathological covariate in breast prognostic models. They
examined the expression of 14 biomarkers out of the 21
present in the Oncotype Dx test (Genomic Health) in
addition to tumor characteristics found in NPI. They
showed that in lymph node negative ER+ tumors, three
biomarkers Aurora Kinase 1, CD68 and HER-2 provided
additional predictive information. The inclusion of other
factors such as vascular invasion, basal phenotype and
HER-2 status has also been considered. Of these factors,
the one with the most evidence to support its inclu-
sion is vascular invasion in patients with node-
negative disease [29, 30].
Since the survival factor GP88 (progranulin) is prefer-
entially expressed in invasive ductal carcinoma and plays
a role in breast cancer cell aggressiveness, we have hy-
pothesized that measuring GP88 expression in tumor
tissues can also provide additional risk prediction infor-
mation and increase the value of NPI determination. We
have shown previously that GP88 expression was associ-
ated with decreased DFS for patients with ER+ IDC [22].
We show here that determination of GP88 tumor tissue
expression further stratifies ER+ IDC patients by their
DFS within each NPI category. This would suggest that
GP88 provides additional information to that provided
by NPI alone and thus can be useful for risk manage-
ment of the patients. It is interesting to note that the
NPI >5.4 group of patients with a low GP88 expression
(Fig. 2c) had DFS outcome similar to the low NPI cat-
egory with high GP88 expression (Fig. 2a). This finding
would suggest that even for the GPG outcome group
(NPI <3.4), the fact of having a tumor GP88 expression
of 3+ brings this subset of patients to a similar DFS as
the PPG outcome group (NPI >5.4). This would suggest
that a combination of low NPI score and low GP88
score is required to produce a favorable DFS outcome.
Additionally, no matter which NPI group the patient is
stratified into, having a low GP88 score contributes to a
better DFS outcome.
We do not know whether GP88 expression would have
the same impact as an independent risk factor for pa-
tients that have ER negative breast tumors. The fact that
GP88 expression down regulates ER expression and
drives ER+ breast cell lines to become estrogen inde-
pendent would suggest that GP88 could also be a useful
prognostic factor in conjunction with NPI for patients
with ER− tumors [17]. However, this possibility needs to
be directly investigated pending the availability of suit-
able ER− cases with proper clinical outcomes.
Based on the results described here, the present study
provides supportive evidence that routine GP88 deter-
mination can be used in the clinic as a complement to
NPI stratification to improve risk prognostication for an
individual patient, particularly during the first 5 years
post- diagnosis of invasive breast cancer. GP88 expres-
sion can be measured by IHC in a fast, reproducible and
cost effective way. The fact that GP88 determination can
enhance the predictive value of NPI would indicate the
usefulness of GP88 IHC test along with other bio-
markers measured as per the standard of care such ER,
PR, HER-2 and Ki67.
Tumor expression of the proliferation antigen Ki67 is
currently used to assess the prognosis of cancer patients
[31]. In addition, recently, prognostic value of Ki67 ex-
pression was demonstrated after short-term pre-surgical
endocrine therapy for primary breast cancer [32]. It is
interesting to note that GP88 is a growth factor shown
to upregulate proliferation markers and as such could
complement the information provided by measuring
Table 5 CPH model for DFS
Variable Hazard Estimate SE Chi-square P > ChiSq Ratio
GP88 = 3+ 1.19337 0.22639 27.7862 <.0001 3.298
NPI >3.4 0.75622 0.29057 6.7733 0.0093 2.130
NPI >5.4 0.64347 0.22371 8.2738 0.0040 1.903
Table 6 CPH model for OS
Variable Hazard Estimate SE Chi-square P > ChiSq Ratio
GP88 = 3+ 0.63731 0.20018 10.1362 0.0015 1.891
NPI >3.4 0.24870 0.16564 2.2544 0.1332 1.282
NPI >5.4 0.66977 0.17789 14.1766 0.0002 1.954
Table 4 Significance of GP88 within NPI groupings
NPI DFS OS
≤3.4 0.0698 0.2331
3.4 to 5.4 0.0002 0.0628
>5.4 0.0005 0.0343
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Ki67 expression. In support of this possibility, we have
reported previously that high GP88 expression in IDC
positively correlated with Ki67 index [21]. A small retro-
spective study of 85 cases of breast cancer patients with
ER+ IDC further demonstrated a correlation between
GP88 and Ki-67 (p < 0.004). In this study, it was interest-
ing to note that the combined GP88 and Ki-67 scores
were statistically associated (p = <0.03) with OncoType
Dx® recurrence score [33]. Retrospective studies with lar-
ger number of cases in the lower NPI category and most
importantly, prospective studies that include GP88 ex-
pression as part of a panel of prognostic and predictive
markers will be useful to further validate GP88 diagnos-
tic utility.
Conclusion
The data suggest that the determination of GP88 tumor
expression at time of diagnosis for early stage breast
cancer patients could provide additional survival infor-
mation to that provided by NPI alone and thus may be
useful for risk management of patients diagnosed with
breast cancer.
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